ArriVent BioPharma, Inc.
AVBP
$34.00
$0.180.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 32.72% | -74.30% | -68.99% | -42.66% | -269.68% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 116.91% | -35.40% | 303.00% | 307.58% | 263.36% |
| Change in Net Operating Assets | 40.63% | 32.90% | -235.28% | -2.87% | -220.92% |
| Cash from Operations | 38.40% | -89.81% | -119.01% | -36.87% | -265.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -90.27% | 63.01% | -- | -- | -- |
| Cash from Investing | -90.27% | 63.01% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 705.89% | 63,067.27% | 16,126.93% | 20,676.03% | -96.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 711.85% | 63,036.36% | 16,183.43% | 20,592.56% | -96.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 167.80% | 67.81% | 99.41% | 435.93% | -114.63% |